Starpharma Holdings Limited
Starpharma is a world leader in the development of nanotechnology-based pharmaceuticals and through its US-based subsidiary Dendritic Nanotechnologies, a range of life science and industrial uses.
Starpharma is listed on the Australian Stock Exchange (ASX: SPL) and its securities also trade in the US under the American Depositary Receipts program (USOTC: SPHRY).
Starpharma's lead development candidates are based on dendrimer nanotechnology. Dendrimers are man-made, nano-sized compounds with unique properties that make them useful to the health and pharmaceutical industry as both enhancements to existing products and as products that are entirely new. Dendrimers are constructed by the successive addition of layers to the branching groups. Each new layer is called a generation. The final generation incorporates the surface molecules that give the dendrimer the desired function for medical, electronic, chemical and materials applications. The innate adaptability of dendrimers is one of their most valuable advantages when applied to the field of medicine.
PO Box 6535
Central, VIC 8008 AUSTRALIA
61 3 8532 2700
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||